![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Myasthenia Gravis Drug
FDA Approves Myasthenia Gravis Drug
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
October 27, 2017
The FDA approved Alexion Pharmaceuticals’ myasthenia gravis medication Soliris (eculizumab) for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive.
Myasthenia gravis is a progressive autoimmune neuromuscular disease that most commonly begins for women before the age of 40 and men after the age of 60.
Current therapies are ineffective for 10-15 percent of gMG patients, Alexion said.
Upcoming Events
-
21Oct